BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199-Reference-Cited by-同舟云学术

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Published:2016-06-23 Issue:25 Volume:127 Page:3192-3201
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Bojarczuk Kamil¹²,Sasi Binu K.¹,Gobessi Stefania¹,Innocenti Idanna³,Pozzato Gabriele⁴,Laurenti Luca³,Efremov Dimitar G.¹

Affiliation:

1. Molecular Hematology, International Centre for Genetic Engineering & Biotechnology, Trieste, Italy;

2. Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland;

3. Department of Hematology, Catholic University Hospital “A. Gemelli,” Rome, Italy; and

4. Department of Medical and Surgical Sciences, University of Trieste, Trieste, Italy

Abstract

Key Points BCR signals induce ABT-199 resistance in CLL cells by upregulating Mcl-1. SYK inhibitors prevent BCR-mediated Mcl-1 induction more effectively than BTK or PI3Kδ inhibitors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/25/3192/1354224/3192.pdf

Reference47 articles.

1. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.;Packham;Immunology,2005

2. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia.;Buggins;Leuk Res,2010

3. miR-15 and miR-16 induce apoptosis by targeting BCL2 [published correction appears in Proc Natl Acad USA. 2006;103(7):2464].;Cimmino;Proc Natl Acad Sci USA,2005

4. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.;Dal-Bo;J Transl Med,2009

5. CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack.;Kater;Br J Haematol,2004

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need;International Journal of Molecular Sciences;2024-01-27

2. Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies;International Journal of Molecular Sciences;2023-11-24

3. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples;Blood;2023-08-03

4. PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis;Journal of Clinical Investigation;2023-07-03

5. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia;Frontiers in Oncology;2023-03-20